Company Information

  

Address: SMEDELAND 36
2600 GLOSTRUP 
City: COPENHAGEN 
State:  
Zip Code: 00000 
Telephone: 458-877-3600 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We were founded in 1998 and is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. We intend to be a leader in specialty medicines focusing on metabolic and gastrointestinal diseases and other specialty disease areas with significant unmet medical needs. We have a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim. Our pipeline focuses on gastrointestinal, metabolic and other specialty diseases where we believe that the present standard of care is inadequate and where we have the resources to advance our peptide-based product candidates into the later stages of clinical development, including registration and commercialization, while opportunistically considering partnership relationships that may arise. We have a track record of successfully inventing and developing novel peptide-based product candidates.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
There's no share overview data.

Key Financial Ratios and Statistics

FYE:

Profitability   Leverage  
Net Inc/Comm EquityNATotal Liab/Total AssetsNA
Net Inc/Total AssetsNATotal Liab/Inv CapNA
Net Inc/Inv CapNATotal Liab/Comm EquityNA
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick RatioNA
Inventory TurnoverNACurrent RatioNA
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  3/31/2017 12/31/2016 12/31/2015
Total Revenues(Net Sales) 11.16 33.30 27.32
Cost of Goods Sold NA NA NA
Selling & Admin Exps 1.41 7.21 4.22
Operating Income -0.48 -16.41 -11.84
Interest Exp 3.62 6.29 6.17
Pretax Income -3.98 -22.61 -17.44
Other Income 0.11 0.08 0.57
Net Income Bef Extraordinary ... NA NA NA
Net Income -3.79 -21.83 -16.59

Balance Sheet (Millions)

Assets 3/31/2017 12/31/2016 12/31/2015
Cash & Short Term Investments 59.98 47.80 64.08
Receivables - Total 2.93 3.18 25.40
Inventories - Total NA NA NA
Total Current Assets 65.77 52.94 89.83
Net Property, Plant & Equipment 2.05 1.94 2.40
Total Assets 68.20 98.54 92.61
Liabilities      
Accounts Payable 3.20 2.80 3.16
Debt in Current Liabilities NA NA NA
Total Current Liabilities 13.66 12.42 10.34
Long-Term Debt NA NA NA
Total Liabilities 31.86 59.07 55.89
Stockholder's Equity      
Minority Interest NA NA NA
Preferred Stock NA NA NA
Common Stock 3.76 3.71 3.55
Retained Earnings -174.83 -168.69 -150.70
Treasury Stock NA NA NA
Total Stockholders' Equity 36.34 39.46 36.72
Total Liabilities and Stockholders' Equity 68.20 98.54 92.61

Cash Flow Summary (Millions)

Categories 3/31/2017 12/31/2016 12/31/2015
Net Cash Provided by Operating Activities -7.46 5.80 -32.72
Net Cash Provided by Investing Activities 44.63 -42.55 -0.23
Net Cash Provided by Financing Activities -25.05 22.29 14.03

Annual Summary Data (Millions)

Year Sales Net Income EPS

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/18143,36110.93




Report Date : 7/17/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.